Acura Pharmaceuticals Inc. is a pharmaceutical company focused on the development and commercialization of deterrents to medication abuse and misuse.[3] As of 2012, the company had several opioid products under development, which would use "Aversion Technology".[4] As of 2014, it was a publicly traded company, listed on NASDAQ under the symbol "ACUR".
History
In 2013, the Company settled Oxecta patent litigation with Impax Laboratories (IPXL) and Par Pharmaceutical.[5]
License agreements
The company has an agreement to license, develop and commercialize opioid analgesic products with King Pharmaceuticals.[6]